BMRN To Seek Review Of PTAB Ruling, CERC Awaits Phase 2 Data In Nov, OCRX Abuzz

BioMarin Pharmaceutical Inc. intends to seek a review of the Patent Trial and Appeal Board's ruling in the composition of matter patent interference pertaining to exon 51 skipping antisense oligonucleotides, which has gone in favor of Sarepta Therapeutics Inc.

from RTT - Biotech http://ift.tt/2d1rqUB
via IFTTT